When choosing a location, consider that it is recommended your patient stays within 2 hours of the Authorized Treatment Center for at least 4 weeks after receiving Kite CAR T therapy. Check back often for updates as new centers will be added on an ongoing basis.
Sweden
Karolinska University Hospital
Karolinska University Hospital
Karolinska University Hospital
Karolinska University Hospital
Karolinska University Hospital
Karolinska University Hospital
Karolinska University Hospital
Karolinska University Hospital
Karolinska University Hospital
Karolinska University Hospital
Kite Pharma EU B.V.
Medical questions
Stay updated about CAR-T
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In maximus ante sem, in eleifend augue dignissim non.
CONTACT
Didn’t find it?
Body copy nequia ne pe velluda periscópico pisan Del moles a volo et landant lis alibust. Lorem Ipsum dolor sit met, consectateue.
ASSOCIATE DIRECTOR - SWEDEN
Helena Svensson
Short intro that makes him more approachable. Velluda periscópico pisan Del moles a volo et landant lis alibust. Lorem Ipsum dolor sit met, consectateue.
| Table example | |
| row1 | 22% |
| row2 | 22% |
| row3 | 22% |
| row4 | 22% |
| row5 | 22% |
| row6 | 22% |
| table footer |
FIGURE 2
Design of the ZUMA-1 trial. ASCT = autologous stem cell transplant. Based on information in Locke FL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther 2017;25:285-95; Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531-44; and the summary of product characteristics for YESCARTA®.1,4,5
FIGURE 3:
SmPC January 2022. Locke FL, et al. Lancet Oncol. 2019;20(1):31-421
References
- KITE Pharma EU B.V. Yescarta 0.4 – 2 x 108 cells dispersion for infusion. Summary of product characteristics. January 2022.
- Locke FL, et al. Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review. JAMA Oncol 2020;6:281-90.
- Ghobadi, A. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma. Curr Res Transl Med 2018;66:43-49.
- Locke FL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther 2017;25:285-95.
- Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531-44.
- Jacobson C, et al. Long-term survival and gradual recovery of b cells in patients with refractory large B Cell lymphoma treated with axicabtagene ciloleucel (axi-cel). 62nd American Society of Hematology Annual Meeting and Exposition, 5–8 December 2020; virtual meeting: Poster 1187.
- Fesnak A, et al. CAR-T cell therapies from the transfusion medicine perspective. Transfus Med Rev 2016;30:139-45.
Report adverse events to Gilead
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In maximus ante sem, in eleifend augue dignissim non.